Torrent Pharmaceuticals to acquire Curatio Healthcare for ₹2,000 crore

Torrent Pharmaceuticals has entered into definitive agreements to acquire 100% of Curatio Healthcare for ₹2,000 crore, the company said in a regulatory filing

September 27, 2022 05:46 pm | Updated 05:46 pm IST - New Delhi

Image for representation purpose only.

Image for representation purpose only. | Photo Credit: Special Arrangement

Torrent Pharmaceuticals on September 27 said it will acquire Curatio Healthcare for ₹2,000 crore to strengthen its presence in the dermatology segment.

The company has entered into definitive agreements to acquire 100% of Curatio Healthcare for ₹2,000 crore, Torrent Pharmaceuticals said in a regulatory filing.

“The consideration includes ₹115 crore [on the date of signing] of cash and cash equivalents in the acquired business indicating an enterprise value of ₹1,885 crore,” it added.

The acquisition offers Torrent the opportunity to enhance its presence in dermatology with a differentiated portfolio and is a strong strategic fit, Torrent Pharmaceuticals Director Aman Mehta said.

“Curatio has built a commendable set of high market share brands in cosmetic and pediatric dermatology that we look forward to adding to our product offerings,” he added.

Chennai-headquartered Curatio has a portfolio of over 50 brands, including Tedibar, Atogla, Spoo, B4 Nappi and Permite, in the cosmetic dermatology segment in India. Its top ten brands account for around 75% of total revenue.

It clocked a revenue of ₹224 crore in FY22 and dermatology accounts for 82% of Curatio’s revenue, the filing said.

The acquisition will catapult Torrent Pharma into the league of top 10 players in the dermatology segment and make it a leader in the cosmetic dermatology space, the company said.

“With this acquisition, Torrent Pharma will add a field force of 600 medical representatives and a distribution network of 900 stockists,” the filing added.

Besides the promoters of Curatio, Sequoia and ChrysCapital will be exiting from the company through the transaction.

The transaction is subject to conditions precedent and is expected to close within one month, Torrent Pharma said.

Top News Today


Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.